START for BioTech
Your most valuable assets need the network purpose-built to move it forward
START helps biotech sponsors reach critical development milestones faster through rapid activation, scientific expertise, and one of the world’s largest dedicated early-phase oncology research networks.
US & Europe
Investigators
Patients
Patient Doses
Drugs Approved
Moving Impact Forward
Future patients are counting on your molecule. Reaching them requires funding. START is the patient-driven, scientifically rigorous, fast-moving cancer research network that helps you achieve the milestones your organization needs to fulfill its mission.
Read the case study to see how START’s trial performance enabled one biotech to secure $210M in funding to-date.
Accelerating trials – Advancing Biotech
START Was Built for Biotech
2x
Benchmark Enrollment compared to other large institutions
4
Week Site Activation helping you rapidly achieve “first patient in” milestones
5
Days data into EDC at the highest levels of quality
ENGAGEMENT MODELS DESIGN TO MOVE YOU FASTER
SuperSTART: A Sponsor’s Competitive Edge in Early-Phase Oncology Trials
SuperSTART (US)
Guaranteed Accelerated Activation Reduced to 4 Weeks
8 Weeks
4 Weeks
SuperSTART (EU)
Guaranteed Accelerated Activation Reduced to 8 Weeks
12 Weeks
8 Weeks
SuperSTART → Guaranteed Study Activation in 4 Weeks
130+
Sites Activated Across 65+ Studies with SuperSTART Since Launch (July 2025)
15 Day
Average from Site Selection to Activation
25
Studies Dosed the First Patient on the Trial
34
Of Those Studies Utilized 2 or More START Sites
45+
Biopharmaceutical Sponsor Utilizing SuperSTART to Activate Their Studies Quicker
100%
Adherence to SuperSTART Timelines
superstart
Why SuperSTART Works
- Centralized activation team focused solely on startup tasks
- Standardized contracts, budgets, and templates across the START Network
- Real-time progress tracking to ensure rapid site readiness
See It in Action
Examples of Assets We Have Supported
License
$848M License
First Patient Dosed
Total Raised
$1.1B Raised
First Patient Dosed
CSPC license
$685M License
First Patient Dosed
Financing
$250M Financing
First Patient Dosed
Venture Funding
$260M Raised
First Patient Dosed
Venture Funding
$101M Raised
First Patient Dosed
